| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLE |
Department of Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences (C.F.), Budapest 1083, Hungary; Tupper Research Institute and Department of Medicine, Division of Endocrinology, Diabetes, Metabolism, and Molecular Medicine (S.S., R.M.L.), Tufts-New England Medical Center, Boston, Massachusetts 02111; Departments of Community Health (W.M.R.) and Neuroscience (R.M.L.), Tufts University School of Medicine, Boston, Massachusetts 02111; Thyroid Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (J.W.H., A.C.B.), Boston, Massachusetts 02115; Department of Medicine, Division of Endocrinology, University of Massachusetts Medical School (C.H.E.), Worcester, Massachusetts 01655; and Institute of Biochemistry, University of Leipzig (A.B.-S.), Leipzig 04103, Germany
Address all correspondence and requests for reprints to: Ronald M. Lechan M.D., Ph.D., Division of Endocrinology, Box 268, Tufts-New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111. E-mail: rlechan{at}lifespan.org.
Neuropeptide Y (NPY) is one of the most important hypothalamic-derived neuropeptides mediating the effects of leptin on energy homeostasis. Central administration of NPY not only markedly stimulates food intake, but simultaneously inhibits the hypothalamic-pituitary-thyroid axis (HPT axis), replicating the central hypothyroid state associated with fasting. To identify the specific NPY receptor subtypes involved in the action of NPY on the HPT axis, we studied the effects of the highly selective Y1 ([Phe7,Pro34]pNPY) and Y5 ([chicken pancreatic polypeptide1–7, NPY19–23, Ala31, Aib32 (aminoisobutyric acid), Q34]human pancreatic polypeptide) receptor agonists on circulating thyroid hormone levels and proTRH mRNA in hypophysiotropic neurons of the hypothalamic paraventricular nucleus. The peptides were administered continuously by osmotic minipump into the cerebrospinal fluid (CSF) over 3 d in ad libitum-fed animals and animals pair-fed to artificial CSF (aCSF)-infused controls. Both Y1 and Y5 receptor agonists nearly doubled food intake compared with that of control animals receiving aCSF, similar to the effect observed for NPY. NPY, Y1, and Y5 receptor agonist administration suppressed circulating levels of thyroid hormones (T3 and T4) and resulted in inappropriately normal or low TSH levels. These alterations were also associated with significant suppression of proTRH mRNA in the paraventricular nucleus, particularly in the Y1 receptor agonist-infused group [aCSF, NPY, Y1, and Y5 (density units ± SEM), 97.2 ± 8.6, 39.6 ± 8.4, 19.9 ± 1.9, and 44.6 ± 8.4]. No significant differences in thyroid hormone levels, TSH, or proTRH mRNA were observed between the agonist-infused FSanimals eating ad libitum and the agonist-infused animals pair-fed with vehicle-treated controls. These data confirm the importance of both Y1 and Y5 receptors in the NPY-mediated increase in food consumption and demonstrate that both Y1 and Y5 receptors can mediate the inhibitory effects of NPY on the HPT axis.
This article has been cited by other articles:
 |
|
 |
|
  M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kakui and K. Kitamura Direct Evidence that Stimulation of Neuropeptide Y Y5 Receptor Activates Hypothalamo-Pituitary-Adrenal Axis in Conscious Rats via both Corticotropin-Releasing Factor- and Arginine Vasopressin-Dependent Pathway Endocrinology, June 1, 2007; 148(6): 2854 - 2862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y.-L. Yu, C.-H. Pon, H.-C. Ku, C.-T. Wang, and Y.-H. Kao A preprogalanin cDNA from the turtle pituitary and regulation of its gene expression Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1649 - R1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K J Oliveira, G S M Paula, R H Costa-e-Sousa, L L Souza, D C Moraes, F H Curty, and C C Pazos-Moura Peptide YY (PYY)3-36 modulates thyrotropin secretion in rats. J. Endocrinol., November 1, 2006; 191(2): 459 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gelegen, D. A. Collier, I. C. Campbell, H. Oppelaar, and M. J. H. Kas Behavioral, physiological, and molecular differences in response to dietary restriction in three inbred mouse strains Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E574 - E581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perello, R. C. Stuart, and E. A. Nillni The Role of Intracerebroventricular Administration of Leptin in the Stimulation of Prothyrotropin Releasing Hormone Neurons in the Hypothalamic Paraventricular Nucleus Endocrinology, July 1, 2006; 147(7): 3296 - 3306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Tulipano, A V Vergoni, D Soldi, E E Muller, and D Cocchi Characterization of the resistance to the anorectic and endocrine effects of leptin in obesity-prone and obesity-resistant rats fed a high-fat diet J. Endocrinol., November 1, 2004; 183(2): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chen, S. M. Williams, K. L. Grove, and M. S. Smith Melanocortin 4 Receptor-Mediated Hyperphagia and Activation of Neuropeptide Y Expression in the Dorsomedial Hypothalamus during Lactation J. Neurosci., June 2, 2004; 24(22): 5091 - 5100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guo, K. Bakal, Y. Minokoshi, and A. N. Hollenberg Leptin Signaling Targets the Thyrotropin-Releasing Hormone Gene Promoter in Vivo Endocrinology, May 1, 2004; 145(5): 2221 - 2227. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
